GSK reports 38% decline in profits during 1QCY19

Mar-19

Mar-18

% Change

Sales

               3,872,871,492

               3,628,148,463

6.75%

Cost of Sales

            (2,799,319,548)

            (2,430,177,900)

15.19%

Gross Profit

               1,073,551,944

               1,197,970,563

-10.39%

Selling, marketing and distribution expenses

                (697,075,958)

                (665,105,230)

4.81%

Administrative expenses

                  (71,130,949)

                  (72,878,182)

-2.40%

Other operating expenses

                  (22,449,200)

                  (32,282,765)

-30.46%

Other income

                     11,002,169

                     21,035,088

-47.70%

Profit from operations

                  293,898,006

                  448,739,474

-34.51%

Finance cost

                  (38,135,246)

                  (66,711,272)

-42.84%

Profit before taxation

                  255,762,760

                  382,028,202

-33.05%

Taxation

                  (88,448,076)

                (113,286,910)

-21.93%

Profit after taxation from continuing operations

                  167,314,684

                  268,741,292

-37.74%

(Loss)/Profit after taxation from discontinued operations

                                      -  

                                      -  

Total profit after taxation

                  167,314,684

                  268,741,292

-37.74%

Earnings per share (Rupees)

                                  1.43

                                  2.30

-37.83%